BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 30653612)

  • 1. Relative cerebral flow from dynamic PIB scans as an alternative for FDG scans in Alzheimer's disease PET studies.
    Peretti DE; Vállez García D; Reesink FE; van der Goot T; De Deyn PP; de Jong BM; Dierckx RAJO; Boellaard R
    PLoS One; 2019; 14(1):e0211000. PubMed ID: 30653612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Early-Phase 11C-Deuterium-l-Deprenyl and 11C-Pittsburgh Compound B PET for Assessing Brain Perfusion in Alzheimer Disease.
    Rodriguez-Vieitez E; Carter SF; Chiotis K; Saint-Aubert L; Leuzy A; Schöll M; Almkvist O; Wall A; Långström B; Nordberg A
    J Nucl Med; 2016 Jul; 57(7):1071-7. PubMed ID: 26912447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparability of [
    Rodriguez-Vieitez E; Leuzy A; Chiotis K; Saint-Aubert L; Wall A; Nordberg A
    J Cereb Blood Flow Metab; 2017 Feb; 37(2):740-749. PubMed ID: 27107028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biopathological Significance of Early-Phase Amyloid Imaging in the Spectrum of Alzheimer's Disease.
    Bunai T; Kakimoto A; Yoshikawa E; Terada T; Ouchi Y
    J Alzheimers Dis; 2019; 69(2):529-538. PubMed ID: 31104023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of 10-minute post-injection 11C-PiB PET and its correlation with 18F-FDG PET in older adults who are cognitively healthy, mildly impaired, or with probable Alzheimer's disease.
    Carneiro CG; Faria DP; Coutinho AM; Ono CR; Duran FLS; da Costa NA; Garcez AT; da Silveira PS; Forlenza OV; Brucki SMD; Nitrini R; Busatto G; Buchpiguel CA
    Braz J Psychiatry; 2022 Aug; 44(5):495-506. PubMed ID: 36420910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease.
    Förster S; Yousefi BH; Wester HJ; Klupp E; Rominger A; Förstl H; Kurz A; Grimmer T; Drzezga A
    Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1927-36. PubMed ID: 22926714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology.
    Laforce R; Tosun D; Ghosh P; Lehmann M; Madison CM; Weiner MW; Miller BL; Jagust WJ; Rabinovici GD
    Neuroimage Clin; 2014; 4():508-16. PubMed ID: 24818077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects.
    Mountz JM; Laymon CM; Cohen AD; Zhang Z; Price JC; Boudhar S; McDade E; Aizenstein HJ; Klunk WE; Mathis CA
    Neuroimage Clin; 2015; 9():592-8. PubMed ID: 26640770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11C-labeled Pittsburgh compound B.
    Meyer PT; Hellwig S; Amtage F; Rottenburger C; Sahm U; Reuland P; Weber WA; Hüll M
    J Nucl Med; 2011 Mar; 52(3):393-400. PubMed ID: 21321269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regional association of pCASL-MRI with FDG-PET and PiB-PET in people at risk for autosomal dominant Alzheimer's disease.
    Yan L; Liu CY; Wong KP; Huang SC; Mack WJ; Jann K; Coppola G; Ringman JM; Wang DJJ
    Neuroimage Clin; 2018; 17():751-760. PubMed ID: 29527482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic role of 11C-Pittsburgh compound B retention patterns and glucose metabolism by fluorine-18-fluorodeoxyglucose PET/CT in amnestic and nonamnestic mild cognitive impairment patients.
    Jiménez-Bonilla JF; Banzo I; De Arcocha-Torres M; Quirce R; Martínez-Rodríguez I; Lavado-Pérez C; Bravo-Ferrer Z; Rodríguez-Rodríguez E; Sánchez-Juan P; Carril JM
    Nucl Med Commun; 2016 Nov; 37(11):1189-96. PubMed ID: 27341411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.
    Shin J; Lee SY; Kim SJ; Kim SH; Cho SJ; Kim YB
    Neuroimage; 2010 Aug; 52(2):488-96. PubMed ID: 20385246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of PIB-PET as a dual pathological and functional biomarker in AD.
    Forsberg A; Engler H; Blomquist G; Långström B; Nordberg A
    Biochim Biophys Acta; 2012 Mar; 1822(3):380-5. PubMed ID: 22115832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can 11C-PiB-PET Relative Delivery R1 or 11C-PiB-PET Perfusion Replace 18F-FDG-PET in the Assessment of Brain Neurodegeneration?
    Oliveira FPM; Moreira AP; de Mendonça A; Verdelho A; Xavier C; Barroca D; Rio J; Cardoso E; Cruz Â; Abrunhosa A; Castelo-Branco M
    J Alzheimers Dis; 2018; 65(1):89-97. PubMed ID: 30056421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.
    Engler H; Forsberg A; Almkvist O; Blomquist G; Larsson E; Savitcheva I; Wall A; Ringheim A; Långström B; Nordberg A
    Brain; 2006 Nov; 129(Pt 11):2856-66. PubMed ID: 16854944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain Amyloid PET Tracer Delivery is Related to White Matter Integrity in Patients with Mild Cognitive Impairment.
    Brown EE; Rashidi-Ranjbar N; Caravaggio F; Gerretsen P; Pollock BG; Mulsant BH; Rajji TK; Fischer CE; Flint A; Mah L; Herrmann N; Bowie CR; Voineskos AN; Graff-Guerrero A;
    J Neuroimaging; 2019 Nov; 29(6):721-729. PubMed ID: 31270885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Head-to-head comparison of 11C-PiB and 18F-FC119S for Aβ imaging in healthy subjects, mild cognitive impairment patients, and Alzheimer's disease patients.
    Byun BH; Kim BI; Park SY; Ko IO; Lee KC; Kim KM; Kim YK; Lee JY; Bu SH; Kim JH; Chi DY; Ha JH; Lim SM
    Medicine (Baltimore); 2017 Mar; 96(12):e6441. PubMed ID: 28328855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
    Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
    J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brain Network Alterations in Alzheimer's Disease Identified by Early-Phase PIB-PET.
    Fu L; Liu L; Zhang J; Xu B; Fan Y; Tian J
    Contrast Media Mol Imaging; 2018; 2018():6830105. PubMed ID: 29531506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of dual-biomarker PIB-PET and dual-tracer PET in AD diagnosis.
    Fu L; Liu L; Zhang J; Xu B; Fan Y; Tian J
    Eur Radiol; 2014 Nov; 24(11):2800-9. PubMed ID: 25097125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.